Several molecules have already been suggested as promising targets of CAFs-based therapy; Targeting FAP, SDF-CXCR4, HGF-Met, TGF-β, PDGF-C and VEGF signaling pathways attenuated tumor growth and tumor progression, as well as reducing innate drug resistance[17–19]. The gene discussed is TGFB1; the disease is neoplasm.